Search

Your search keyword '"Kenet, G."' showing total 705 results

Search Constraints

Start Over You searched for: Author "Kenet, G." Remove constraint Author: "Kenet, G."
705 results on '"Kenet, G."'

Search Results

1. Venous thromboembolism characteristics and outcomes among RIETE patients tested and untested for inherited thrombophilia

2. Bleeding phenotype according to factor level in 825 children with nonsevere hemophilia: data from the PedNet cohort

3. Clinical outcomes after discontinuing anticoagulant therapy in patients with first unprovoked venous thromboembolism

4. Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU

5. Switching from Sucrose-Formulated rFVIII to Octocog Alfa (BAY 81-8973) Prophylaxis Improves Bleed Outcomes in the LEOPOLD Clinical Trials

6. A prognostic score to identify women at increased risk for abnormal uterine bleeding during anticoagulation for venous thromboembolism

7. COVID-19–associated venous thromboembolism: risk of recurrence and major bleeding

8. Venous thromboembolism characteristics, treatment and outcomes in young adults: findings from the Registro Informatizado de Enfermedad TromboEmbólica registry

9. Bleeding phenotype according to factor level in 825 children with non-severe hemophilia; data from the PedNet cohort

10. Heart Rate and Mortality in Patients With Acute Symptomatic Pulmonary Embolism

11. Venous thromboembolism characteristics and outcomes among RIETE patients tested and untested for inherited thrombophilia

12. The value‐based healthcare approach to haemophilia: Development of outcome measures for the evaluation of care of people with haemophilia

13. PCR191 Assessing Quality of Care in Haemophilia Using a Value-Based Healthcare Approach

14. A prognostic score to identify women at increased risk for abnormal uterine bleeding during anticoagulation for venous thromboembolism

16. OC 49.1 3K3A-Activated Protein C Treatment Exerts Anti-Inflammatory and Blood Barrier Stabilizing Effects in the Retina, and Inhibits Choroidal Neovascularization

18. OC 20.1 Bleeding, FVIII Activity, and Safety 3 Years After Gene Transfer with Valoctocogene roxaparvovec: Results from GENEr8-1

20. PB0680 Clinical Characteristics, Therapy and Outcome of Children with Hemophilia B and Inhibitors: a PedNet Study

21. OC 43.1 A Survey on Clinical Praxis in Initiating Emicizumab Prophylaxis in Previously Untreated Patients in the PedNet Centers

25. Venous thromboembolism characteristics, treatment and outcomes in young adults: findings from the Registro Informatizado de Enfermedad TromboEmbólica registry

28. Determinants of bleeding before and during immune tolerance in 222 boys with severe hemophilia A and inhibitors >5 BU

30. Encore - emicizumab prophylaxis for the treatment of infants with severe hemophilia A without Factor VIII inhibitors: results from the interim analysis of the HAVEN 7 study

31. Efficacy and safety of valoctocogene roxaparvovec gene transfer for severe hemophilia A: results from the GENEr8-1 three-year analysis

34. Anticoagulation in pediatric cancer-associated venous thromboembolism: a subgroup analysis of EINSTEIN-Jr

37. Heart Rate and Mortality in Patients With Acute Symptomatic Pulmonary Embolism

38. Liver status and outcomes in patients without previous known liver disease receiving anticoagulant therapy for venous thromboembolism

39. BAY 81–8973 safety and efficacy for prophylaxis and treatment of bleeds in previously treated children with severe haemophilia A: results of the LEOPOLD Kids Trial

41. Rate of inhibitor development in previously untreated hemophilia A patients treated with plasma‐derived or recombinant factor VIII concentrates: a systematic review

47. Second interim analysis results from the STASEY trial: A single-arm, multicentre, open-label, phase III clinical trial to evaluate the safety and tolerability of emicizumab prophylaxis in persons with haemophilia A (PwHA) with FVIII inhibitors

48. Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria

49. Long-term follow-up of neonatal intracranial haemorrhage in children with severe haemophilia

Catalog

Books, media, physical & digital resources